ArticleJournal of the Canadian Association of Gastroenterology2020

The Argument Against a Biosimilar Switch Policy for Infliximab in Patients with Inflammatory Bowel Disease Living in Alberta.

Gilaad G Kaplan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.